Fintel reports that on March 7, 2025, Leerink Partners initiated coverage of CorMedix (NasdaqGM:CRMD) with a Outperform ...

We feel now is a pretty good time to analyse CorMedix Inc.'s ( NASDAQ:CRMD ) business as it appears the company may be... BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc ...

Shares of CorMedix Inc. (NASDAQ:CRMD – Get Free Report) have been assigned an average recommendation of “Buy” from the eight research firms that are covering the firm, Ratings reports. Seven analysts ...

Steward Partners Investment Advisory LLC boosted its position in CorMedix Inc. (NASDAQ:CRMD – Free Report) by 2.2% during the ...

Leerink analyst Roanna Ruiz initiated coverage of CorMedix (CRMD) with an Outperform rating and $18 price target The firm believes the ...

Elliott Investment Management made several portfolio moves in the fourth quarter, closing multiple options positions and shaking up the activist firm's technology exposure. Shares of CorMedix ...

Short interest in Cormedix Inc (NASDAQ:CRMD) increased during the last reporting period, rising from 7.18M to 7.39M. This put 12.19% of the company's publicly available shares short. Short ...

BERKELEY HEIGHTS, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life ...

The firm increased its portfolio allocation in CRMD by 114.89% over the last quarter. VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,732K shares representing 2.85% ...